0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Low-Dose Danazol Therapy in Idiopathic Thrombocytopenic Purpura

YEON S. AHN, M.D.; RAVINDRA MYLVAGANAM, Ph.D.; ROLANDO O. GARCIA, M.D.; CHAE I. KIM, B.S.; DIANA PALOW, R.N.; and WILLIAM J. HARRINGTON, M.D.
[+] Article and Author Information

Grant support: in part by grant IR01 AM 33813 from the National Institutes of Health, merit review award 0215 01 from the Veterans Administration Hospital, the Mary Beth Weiss Research Fund, and the Kenneth Chasen Research Fund.

▸Requests for reprints should be addressed to Yeon Soong Ahn, M.D.; Center for Blood Diseases, 1475 N.W. 12 Avenue; Miami, FL 33136.


©1987 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1987;107(2):177-181. doi:10.7326/0003-4819-107-2-177
Text Size: A A A

Although danazol is effective in the treatment of idiopathic thrombocytopenic purpura, its long-term safety and optimal dosage are not well established. We compared low (50 mg/d) and conventional (400 to 800 mg/d) dosages in 24 patients. Thirteen patients received the low dose 1 to 24 months after conventional doses had been discontinued (group 1). Five patients received low doses immediately after the conventional doses (group 2). Six patients were treated with low doses from the outset (group 3). In group 1, similar responses to either dose were seen in 9 patients, whereas there were better responses to conventional doses in 3 and to the lower dose in 1. All patients in group 2 maintained remissions with low doses. There were two excellent-good responses, one fair, and three poor responses in group 3. Side effects were generally less frequent and severe with the low doses. Low-dose danazol is better tolerated but took longer to obtain remissions, and is useful for maintenance therapy in the management of idiopathic thrombocytopenic purpura.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)